Table 4 Summary of systemic antifungal agents administered during the 5-day observation period
Prophylaxis (n = 95) | Empiric strategy (n = 13) | Pre-emptive or curative strategy (n = 11) | Total (N = 119) | |
|---|---|---|---|---|
Missing values | 1 (1) | 0 | 0 | 1 (1) |
Azoles alone | 70 (74) | 2 (15) | 8 (73) | 80 (67) |
Polyenes alone | 10 (11) | 2 (15) | 1 (9) | 13 (11) |
Echinocandins alone | 13 (14) | 9 (69) | 0 | 22 (18) |
Polyenes and azoles | 1 (1) | 0 | 2 (18) | 3 (25) |
Azole type | ||||
N a | 71 | 2 | 10 | 83 |
PO fluconazole | 38 (54) | 1 (50) | 0 | 39 (47) |
IV fluconazole | 6 (8) | 0 | 0 | 6 (7) |
PO posaconazole | 16 (23) | 0 | 2 (20) | 18 (22) |
PO voriconazole | 8 (11) | 0 | 6 (60) | 14 (17) |
IV voriconazole | 3 (4) | 1 (50) | 2 (20) | 6 (7) |
Polyene type | ||||
N a | 11 | 2 | 3 | 16 |
IV liposomal amphotericin B | 8 (73) | 2 (100) | 3 (100) | 13 (81) |
IV conventional amphotericin B | 3 (27) | 0 | 0 | 3 (19) |
Echinocandin type | ||||
N a | 13 | 9 | 0 | 22 |
Caspofungin | 11 (85) | 9 (100) | 0 | 20 (91) |
Micafungin | 2 (15) | 0 | 0 | 2 (9) |